Harrow, Inc. HROW 深 滬
已收盤 02-06 16:00:00 美东时间
47.32
+1.260
+2.74%
華盛通- 最 高48.01
- 今 開46.54
- 成交量 51.26万股
- 最 低 45.6601
- 昨 收 46.06
- 總市值 17.53亿
- 52周最高 54.85
- 市盈率 靜 --
- 換手率 1.38%
- 52周最低 20.85
- 委 比 -60.04%
- 總股本 3703.75万
- 歷史最高 59.23
- 量 比 0.70
- 振 幅 5.10%
- 歷史最低 3.33
- 每 手 1
- 風險率 8.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Harrow shares are trading higher after the company reaffirmed its FY25 revenue guidance.
Harrow shares are trading higher after the company reaffirmed its FY25 revenue ...
02-03 02:39
Harrow Reiterates 2025 Revenue Outlook Of $270M–$280M Driven By Expanding Commercial Footprint And Portfolio Performance
Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting
02-02 20:15
Harrow Health Completes Acquisition of Melt Pharmaceuticals
Harrow Health ( ($HROW) ) has provided an announcement. On November 17, 2025, H...
2025-11-18 21:29
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
2025-11-13 09:58
Ladenburg Thalmann Maintains Buy on Harrow, Raises Price Target to $66
Ladenburg Thalmann analyst Jeffrey Cohen maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $64 to $66.
2025-11-13 03:48
Outset Medical, Gemini Space Station, CoreWeave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mostly lower this morning, with the S&P 500 futures...
2025-11-11 21:29
Harrow shares are trading lower after the company reported worse-than-expected Q3 financial results.
Harrow shares are trading lower after the company reported worse-than-expected ...
2025-11-11 05:16
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Harrow subsidiary ImprimisRx gets new CEO
Harrow (NASDAQ:HROW) announced leadership changes at its wholly-owned subsidiary, ImprimisRx; Frank Mullery has been appointed as CEO and Bridseida Cruz has been appointed as Head of Quality of Impr...
2025-10-06 19:44
ImprimisRx Announces Leadership Changes
Harrow announced leadership changes at its subsidiary ImprimisRx, appointing Frank Mullery as CEO and Bridseida Cruz as Head of Quality. Mullery, with over 20 years in healthcare and pharma, has a track record of scaling businesses and launching successful products. Cruz, with 25 years in quality and operations, specializes in FDA compliance and driving operational efficiency. Harrow’s CEO Mark Baum expressed confidence in their leadership to adv...
2025-10-06 11:00
